Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.» Read More
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.
CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in.
Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.
Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
The biotech industry is off to its best start in over a decade. What's driving the accelerated growth? CNBC's Seema Mody has the details on speculative buyout targets this year.
Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.
Clay Siegall, Seattle Genetics president & CEO, discusses the company's cancer drug, Adcetris, and which new drugs are in the company's pipeline for 2012.
Jeffrey Leiden, Vertex Incoming CEO, and George Scangos, Biogen Idec CEO, discuss Biogen's restructuring and Vertex's Hepatitis C drug.
As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?
Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.
The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.
The biotech sector has surged more than 9% in 2011, so what should investors expect for the new year? Chris Raymond, Robert W. Baird senior biotech analyst, and Karen Anderson, Morningstar senior equity analyst share insight into the sector.
Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.
Cramer goes one-on-one with Questcor CEO Don Bailey to find out more about the company.
Analysis on why the biotech sector is seeing a down trend, with Raghuram Selvaraju, Morgan Joseph TriArtisan senior vice-president/senior biotechnology analyst.
Daniel Junius talks to Cramer about the drug’s recent trial, which was good news for the company’s stock, and when the FDA could get it for approval.